menu
    • menu
    [{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Dipraglurant

    Menu

    Dipraglurant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson Diseas...

                            Details : Following oral administration, ADX48621 (dipraglurant) was rapidly absorbed and readily crossed the blood-brain barrier. In vivo, dipraglurant administration was found to dose-dependently impact the various NMS disease models.

                            Product Name : ADX48621

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 04, 2023

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Armistice Master Fund

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Addex Completes $4.2 Million Equity Financing

                            Details : Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).

                            Product Name : ADX48621

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 26, 2022

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Armistice Master Fund

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Armistice Master Fund

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Addex Raises $4.2 Million in Equity Financing

                            Details : Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).

                            Product Name : ADX48621

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 22, 2022

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Armistice Master Fund

                            Deal Size : $4.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disea...

                            Details : ADX48621 (Dipraglurant (Immediate Release), as a novel orally available mGlu5 NAM, for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).

                            Product Name : ADX48621

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 17, 2022

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

                            Details : ADX48621 (dipraglurant), is a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM. It’s lead indication is levodopa induced dyskinesia associated with Parkinson’s disease, or PD-LID.

                            Product Name : ADX48621

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 27, 2022

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $11.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Addex Successfully Completes $11.5 Million Capital Increase

                            Details : Addex intends to use the net proceeds from the global offering, mainly to advance development of its portfolio of proprietary drug candidates based on its allosteric modulator development capabilities. These include dipraglurant for use in Parkinson's di...

                            Product Name : ADX48621

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 01, 2021

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $11.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed

                            Addex Therapeutics

                            Switzerland arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

                            Details : The double-blind, randomized Phase 2a feasibility study will enroll 15 patients with blepharospasm. It is designed to assess the safety and tolerability of dipraglurant as well as explore its effects on the severity and frequency of blepharospasm signs a...

                            Product Name : ADX48621

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : Dipraglurant

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth